31st October 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Sun Pharma fined Rs 2 crore for openly discharging wastewater in Nawanshahr

The Punjab Pollution Control Board penalized Sun Pharmaceutical Limited Rs 2 crore for releasing effluent in an open space at its production unit in neighboring Taunsa village in Nawanshahr district. The company’s manufacturing capacity must be cut in half.

Laurus Labs receives Form 483 from USFDA with one observation

USFDA has completed a PreApproval Inspection (PAI) with one observation at Laurus Labs’ manufacturing facility in Unit-5, Parawada, Visakhapatnam, Andhra Pradesh. USFDA Form 483 is issued to the firm following an inspection.

This pharma gave breakout above Symmetrical Triangle after making triple bottom; Time to buy?

The S&P BSE Sensex index constituent Dr Reddy’s Laboratories Ltd, which has increased its value by more than 20% since hitting a low of Rs 3,655 in March. For a potential target of Rs 4,800 in the following one to two months, short-term traders can look to buy the stock now or on dips.

Tax authorities in Italy looking into Pfizer profits

The Italian tax authorities are looking into profits recorded by Pfizer Inc’s local affiliate, Pfizer Italia srl. According to Italian law, the police must submit the outcome to the company involved and the state tax agency, which subsequently prepares a so-called deed of acceptance of the assessment and payment of any sum deemed due.

CDSCO Panel approved continuation of clinical trial study for Tofacitinib Ointment 2%

The Central Medicine Standard Control Organization’s (CDSCO) Subject Expert Committee (SEC) has approved the continuation of the clinical study of Intas Pharma’s drug Tofacitinib Ointment 2% in accordance with the approved protocol.

South Africa's health minister seeks for additional pharma investment

African continent has been the subject of several announcements and agreements over the past year, ranging from partnerships to temporary venues. The nation is continuing to hold itself accountable, as per South Africa’s health minister.

FDA extends Amicus muscular disorder treatment review for second time

FDA prolonged for the second time its review of Amicus Therapeutics Inc’s investigational combination medication to treat Pompe illness. The delay was attributed to pandemic-related travel restrictions, which prevented the agency from undertaking a required production site inspection before the decision was due.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?